Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
University Hospital Translational Laboratory, University Hospitals Case Medical Center, Cleveland, Ohio.
J Med Virol. 2017 Jan;89(1):106-111. doi: 10.1002/jmv.24610. Epub 2016 Jul 6.
A lower virulence of HIV-1 subtype C (HIV-1C) is suggested to be related to the global dominance of HIV-1C. In this observational study, combining in vivo (clinical monitoring) and in vitro (genotypic, biochemical, and phenotypic assays), we explored whether HIV-1C from East Africa (HIV-1C ) is more pathogenic due to the evolution of a PYxE-insertion (C ) in the gag-p6 that also could affect the therapy response.
HIV-1B (n = 112) and HIV-1C (n = 128)-infected individuals residing in Sweden were analyzed with regard to Gag-p6 genotype and clinically monitored. Based on the Gag-p6 characteristics, three HIV-1C and one HIV-1 B patient-derived p2-INT-recombinant virus (gag-p2/NCp7/p1/p6/pol-PR/RT/IN) were constructed to analyze viral growth kinetics (VGKs) and drug sensitivity assays. Reverse transcriptase (RT) from the same samples was cloned into the heterodimer expression plasmid (pRT6H-PROT) to analyze catalytic efficiency of RT.
A higher viral failure rate and lower pre-therapy CD4 T-cell counts were observed in HIV-1C -infected patients compared to HIV-1B-infected patients. In Gag-p6, PTAP-duplication was more common in HIV-1C. HIV-1C -infected patients with signature C evidenced very low pre-therapy CD4 T-cell counts and suboptimal gain in CD4 T-cells following therapy, as compared to the non-C -strains indicating higher virulence. VGKs showed a statistically significant higher replication capacity (RC) for the C viruses than the other two non-C strains. No statistically significant difference was observed in the catalytic efficiency among HIV-1C RTs.
This is the first evidence of polymerase independent increased virulence and RC in HIV-1C following PYxE-insertion that is associated with suboptimal CD4 T-cell gain following therapy initiation. J. Med. Virol. 89:106-111, 2017. © 2016 Wiley Periodicals, Inc.
HIV-1 亚型 C(HIV-1C)的毒力较低,这可能与 HIV-1C 在全球的主导地位有关。在这项观察性研究中,我们结合体内(临床监测)和体外(基因、生化和表型分析)研究,探索东非的 HIV-1C(HIV-1C)是否由于 gag-p6 中的 PYxE-插入(C)的进化而具有更高的致病性,这种进化也可能影响治疗反应。
分析了居住在瑞典的 HIV-1B(n=112)和 HIV-1C(n=128)感染者的 gag-p6 基因型,并进行了临床监测。根据 gag-p6 的特征,构建了三个 HIV-1C 和一个 HIV-1B 患者衍生的 p2-INT 重组病毒(gag-p2/NCp7/p1/p6/pol-PR/RT/IN),以分析病毒生长动力学(VGKs)和药物敏感性试验。从相同样本中克隆逆转录酶(RT)到异二聚体表达质粒(pRT6H-PROT),以分析 RT 的催化效率。
与 HIV-1B 感染者相比,HIV-1C 感染者的病毒失败率更高,治疗前 CD4 T 细胞计数更低。在 gag-p6 中,PTAP 重复更为常见。与非 C 株相比,具有特征 C 的 HIV-1C 感染者的治疗前 CD4 T 细胞计数非常低,治疗后 CD4 T 细胞的增加也不理想,表明其毒力更高。VGKs 显示 C 型病毒的复制能力(RC)具有统计学意义的显著提高,高于其他两种非 C 株。HIV-1C RT 的催化效率没有统计学上的显著差异。
这是首次在聚合酶独立的情况下,在 PYxE 插入后 HIV-1C 中发现毒力和 RC 增加,这与治疗开始后 CD4 T 细胞获得不理想有关。医学病毒学杂志 89:106-111,2017。© 2016 年 Wiley 期刊,公司。